skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia

Review

(1959) Views  (747) Full article downloads

Authors: Rosaria Di Lorenzo, Alice Brogli

Published Date September 2010 Volume 2010:6(1) Pages 573 - 581
DOI: http://dx.doi.org/10.2147/NDT.S5463

Rosaria Di Lorenzo1, Alice Brogli2

1Department of Mental Health, AUSL-MODENA, Presidio Psichiatrico di Diagnosi e Cura 1, NOCSAE, Baggiovara, Modena, Italy; 2School of Specialization in Psychiatry, University of Modena e Reggio Emilia, Modena, Italy

Abstract: Olanzapine long-acting injection (OLAI) is a crystalline salt composed of olanzapine and pamoic acid, which permits a depot intramuscular formulation of olanzapine. The half-life of olanzapine pamoate is 30 days, and its steady state is reached approximately at 12 weeks. Oral supplementation of olanzapine is not required during OLAI initiation, according to Eli Lilly recommendations, although a study indicated that ≥60% of D2 receptor occupancy was reached only by the fifth injection cycle. To date, a short-term, placebo-controlled study of 8 weeks in acutely ill patients and a long-term, controlled trial of 24 weeks in stabilized patients have been conducted. In both the studies, efficacy and safety were similar to those of oral olanzapine, with the exception of an acute adverse effect, the so-called inadvertent intravascular injection event, which occurred 1–3 hours after the injection with an incidence rate of 0.07% per injection. It consisted of symptoms that are similar to those reported in cases of oral olanzapine overdose. The most significant studies published to date, on the use of olanzapine pamoate in schizophrenia, are reviewed in this article. The pharmacodynamic and pharmacokinetic profile and related side effects of OLAI are reported.

Keywords: olanzapine pamoate long-acting injection, efficacy, safety






Readers of this article also read:

Emerging treatments in the management of schizophrenia – focus on sertindole
Polyclonal light chains in cerebrovascular disease
Management of depression in elderly stroke patients
Once-monthly paliperidone injection for the treatment of schizophrenia
Greater osteoblast and endothelial cell adhesion on nanostructured polyethylene and titanium
Brief assessment of negative dysmorphic signs
Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility